Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype.

Autor:	Cantó LN; Departament of Neurology, Hospital General Universitario de Elche, Alicante, Spain., Boscá SC; Neuroimunology and Multiple Sclerosis Research Group, Hospital Universitari i Politècnic La Fe de València, Valencia, Spain., Vicente CA; Neuroimmmunology Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Gil-Perontín S; Neuroimunology and Multiple Sclerosis Research Group, Hospital Universitari i Politècnic La Fe de València, Valencia, Spain., Pérez-Miralles F; Neuroimmmunology Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Villalba JC; Neuroimunology and Multiple Sclerosis Research Group, Hospital Universitari i Politècnic La Fe de València, Valencia, Spain., Nuñez LC; Neuroimunology and Multiple Sclerosis Research Group, Hospital Universitari i Politècnic La Fe de València, Valencia, Spain., Casanova Estruch B; Neuroimmmunology Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in neurology [Front Neurol] 2019 Nov 01; Vol. 10, pp. 1157. Date of Electronic Publication: 2019 Nov 01 (Print Publication: 2019).
DOI:	10.3389/fneur.2019.01157
Abstrakt:	Background and objective: Chronic relapsing inflammatory optic neuritis (CRION) is one of the more common phenotypes related to myelin oligodendrocyte glycoprotein antibodies (MOG-Abs). The absence of specific biomarkers makes distinguishing between CRION and relapsing inflammatory ON (RION) difficult. A recent work has suggested a widespread affectation of the central nervous system in CRION patients. In order to search for a potential CRION marker we have measured brain atrophy in a cohort of patients, stratified by phenotypes: CRION, RION, multiple sclerosis with a history of optic neuritis (MS-ON), and MOG-Abs status. Methods: A cross-sectional study was conducted in 31 patients (seven CRION, 11 RION, and 13 MS-ON). All patients were tested for MOG and aquaporin-4 antibodies (AQ4-Abs). Clinical data were collected. Brain atrophy was calculated by measuring the brain parenchyma fraction (BPF) with Neuroquant® software. Results: Four of seven CRION patients and one of 11 RION patients were positive for MOG-Abs ( p = 0.046) and no MS-ON patients tested positive to MOG-Abs. All patients were negative to AQ4-Abs. The BPF was lower in patients with CRION than patients with RION (70.6 vs. 75.3%, p = 0.019) and similar to that in MS-ON patients. Conclusions: Brain atrophy in idiopathic inflammatory relapsing ON is present in patients with the CRION phenotype. Data from this study reflect that the optic nerve is a main target involved in these patients but not the only one. Our results should be further investigated in comprehensive and prospective studies. (Copyright © 2019 Cantó, Boscá, Vicente, Gil-Perontín, Pérez-Miralles, Villalba, Nuñez and Casanova Estruch.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu